Compare VALN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VALN | GERN |
|---|---|---|
| Founded | 2012 | 1990 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 855.8M | 900.1M |
| IPO Year | 2021 | 1996 |
| Metric | VALN | GERN |
|---|---|---|
| Price | $10.30 | $1.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $15.75 | $3.00 |
| AVG Volume (30 Days) | 19.5K | ★ 9.1M |
| Earning Date | 11-20-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $211,089,992.00 | $183,403,000.00 |
| Revenue This Year | $3.64 | $147.42 |
| Revenue Next Year | $12.23 | $37.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.48 | ★ 522.13 |
| 52 Week Low | $4.56 | $1.04 |
| 52 Week High | $12.25 | $3.12 |
| Indicator | VALN | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 54.24 |
| Support Level | $9.62 | $1.26 |
| Resistance Level | $10.32 | $1.37 |
| Average True Range (ATR) | 0.30 | 0.08 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 62.50 | 52.27 |
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.